RECQL4 and osteosarcoma: In conclusion, our results provide preliminary evidence that RUNX2, CDC5L, MDM2, RECQL4, and CDK4 should be further investigated to determine their roles as predictive biomarkers in osteosarcoma, because collectively, their differential expression correlates with poor response to chemotherapy in our cohort.